CYP2C19 and metabolic dysfunction-associated steatotic liver disease: Diabetes and cardiometabolic diseases are highly associated with NAFLD5–9 and therefore these data further support the hypothesis that NAFLD is involved in reduced clopidogrel efficacy through the downregulation of CYP2C19.